ストックスクリーナーアプリを入手
22.91
1.44%
-0.38
前日終値:
$23.29
開ける：
$23.185
24時間の取引高:
197.02K
Relative Volume:
0.12
時価総額：
$1.44B
収益：
-
当期純損益:
$-107.85M
株価収益率:
-10.37
EPS:
-2.21
ネットキャッシュフロー:
$-106.82M
1週間 パフォーマンス:
+10.04%
1か月 パフォーマンス:
+20.56%
6か月 パフォーマンス:
-44.57%
1年 パフォーマンス:
-33.77%
1日の値動き範囲:
$22.73
$23.31
1週間の範囲:
$20.40
$25.30
52週間の値動き範囲:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
名前
Vera Therapeutics Inc
セクター
電話
650-770-0077
住所
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
22.99 | 1.44B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.70 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.62 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.04 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
559.57 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
239.92 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-05 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2025-01-28 | 開始されました | Goldman | Buy |
| 2024-11-21 | 開始されました | Wells Fargo | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-25 | 開始されました | Oppenheimer | Outperform |
| 2024-01-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 開始されました | Raymond James | Outperform |
| 2023-11-10 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-16 | 開始されました | Guggenheim | Buy |
| 2023-01-04 | ダウングレード | Jefferies | Buy → Hold |
| 2023-01-04 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-07-12 | 開始されました | JP Morgan | Overweight |
| 2022-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-19 | 開始されました | Wedbush | Outperform |
すべてを表示
Vera Therapeutics Inc (VERA) 最新ニュース
Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com
Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus
Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Expands Team with 17 New Hires, Awards Major Stock Options Worth $6M - Stock Titan
H.C. Wainwright maintains $85 target on Vera Therapeutics stock By Investing.com - Investing.com Canada
Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP - Defense World
California State Teachers Retirement System Acquires 6,749 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down – Should You Sell? - Defense World
Biotech Stocks To Watch Today – June 6th - Defense World
Otsuka’s IgAN Data Top Some Vera Results, But To What End? - insights.citeline.com
Vera Therapeutics (VERA) Drops 32% After Trial Results Disappoin - GuruFocus
Vera Therapeutics (VERA) Stock Plummets Over 29% in Major Sell-Off - Daily Chhattisgarh News
Biotech Stock Vera Is Slumping After Monster Gain - Barron's
Vera Therapeutics stock sinks following competitor’s successful trial By Investing.com - Investing.com Nigeria
Vera Therapeutics stock sinks following competitor’s successful trial - Investing.com Australia
Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha
Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Research Analysts Offer Predictions for VERA FY2027 Earnings - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN
FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
(VERA) Trading Advice - news.stocktradersdaily.com
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Vera Therapeutics eyes half billion dollars after kidney drug study - The Business Journals
Vera Therapeutics (VERA) Price Target Increased Amid Positive Tr - GuruFocus
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India
Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus
Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus
Vera Therapeutics Secures $500M Loan Agreement - TipRanks
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph
Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan
Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) PT Set at $65.00 by Scotiabank - Defense World
Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo Finance
These 10 Stocks Blew Past Expectations - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks
H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks
Vera Therapeutics Inc (VERA) 財務データ
収益
当期純利益
現金流量
EPS
Vera Therapeutics Inc (VERA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):